



Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542
Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

Dated: 30th May, 2019

To,
BSE Limited,
PhirozeJeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)
Sub: Compliance under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Filing of Audited Financial Results for the Quarter and Year ended 31st March, 2019

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2019 duly approved by the Board of Directors of the Company, at its meeting held today, the 30th day of May, 2019. The Meeting of Board of Directors of the Company commenced at 11:45 A.M. and concluded at 01:30 P.M.

We are also enclosing a copy of the Auditor's Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further we are enclosing a copy of Declaration given by Managing Director and Chief Financial Officer pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular no. CIR/ CFD/ CMD/56/2016 dated May, 27, 2016.

You are requested to kindly take the same into your records.

Thanking you.

Yours faithfully,

For and on behalf of
Genomic Valley Biotech Limited

Hitesh



Hitesh Kumar
Company Secretary & Compliance officer

Encl: A/A

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,

TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2019

In Rs.

Sr. No.	Particular	For the quarter ended			For the year ended	
		31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue From Operations	3,124,174	2,605,220	2,036,084	9,850,101	5,944,430
II	Other Income	147,579	374	19,082	147,952	124,688
III	Total Revenue (I+II)	3,271,753	2,605,594	2,055,166	9,998,052	6,069,118
IV	Expenses					
	Cost of materials consumed	101,610	219,174	133,790	471,545	452,801
	Purchases of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-
	Employee benefits expense	416,615	436,365	897,939	2,668,923	3,356,398
	Financial costs	-	-	-	-	-
	Depreciation and amortization expense	486,530	524,158	11,990	1,937,408	757,218
	Other expenses	923,359	589,457	328,372	2,573,127	1,129,825
	Total Expenses (IV)	1,928,114	1,769,154	1,372,091	7,651,003	5,696,242
V	Profit / (Loss) before exceptional item and tax (III-IV)	1,343,639	836,440	683,075	2,347,049	372,876
VI	Exceptional Item	-	-	-	-	213,000
VII	Profit/loss before Tax (V-VI)	1,343,639	836,440	683,075	2,347,049	585,876
VIII	Tax expenses					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	22,083	-	244,971	22,083	244,971
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	1,321,556	836,440	438,105	2,324,966	340,905
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	1,321,556	836,440	438,105	2,324,966	340,905
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	1,321,556	836,440	438,105	2,324,966	340,905
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):					
	1) Basic	0.43	0.27	0.14	0.76	0.11
	2) Diluted	0.43	0.27	0.14	0.76	0.11
XVIII	Earning Per Equity Share (for discontinued operation):					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):					
	1) Basic	0.43	0.27	0.14	0.76	0.11
	2) Diluted	0.43	0.27	0.14	0.76	0.11



Statement of Asset and Liabilities

Particulars	As at	
	31/03/2019	31/03/2018
	Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	43,077,029	41,205,043
Capital work in progress	4,885,459	3,767,076
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	-
Loans	20,600,000	20,600,000
Security Deposits	200,000	287,788
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
Total Non-Current Assets	68,762,488	65,859,908
Current Assets		
Inventories	1,187,441	331,798
Financial Assets:	-	-
Investments	-	-
Trade Receivables	583,483	223,362
Cash and Cash equivalents	30,820	33,300
Other Balances with banks	719,824	89,247
Loans	-	-
Other financial assets	-	-
Other Current assets	491,181	204,961
Total Current Assets	3,012,749	882,668
Total Assets	71,775,237	66,742,576
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	30,545,000	30,545,000
Other Equity	17,065,232	14,740,266
Total Equity	47,610,232	45,285,266
Non Current Liabilities		
Financial liabilities		
Borrowings	14,788,077	7,500,000
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	149,433	127,351
Provisions	-	-
Other Non Current liabilities	8,500,000	-
Total Non Current Liabilities	23,437,510	7,627,351



Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	47,474	75,000
Other Financials liabilities	-	-
Provisions	276,370	261,680
Other Current liabilities	403,650	13,493,279
Total Current Liabilities	727,494	13,829,959
TOTAL EQUITY AND LIABILITIES	71,775,237	66,742,576

Notes :

- 1 The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 30, 2019 and the Statutory Auditors of the company have audited these financials results.

- 2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.

- 3 Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.

- 4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.



For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited

Yogesh Agrawal
Yogesh Agrawal
Managing Director
DIN: 01165288

Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 30/05/2019



A.K. Khattar & Associates
Chartered Accountants

112-A, Ground Floor, DDA Complex,
Jhandewalan Extn-1, New Delhi - 110055
Ph: 011-43570260

Annexure - 2

INDEPENDENT AUDITOR'S REPORT

To,

The Board of Directors of
Genomic Valley Biotech Limited
4 K.M. Stone, Beri Chharra Road,
Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh,
Distt-Jhajjar, Haryana-124507

Subject: Independent Auditor's Report on the Audited Financial Results for the Quarter and Year ended 31st March, 2019

Dear Sir/Madam,

1. We have audited the accompanying Statement of Standalone Audited Financial Results of **Genomic Valley Biotech Limited** ('the Company') for the quarter and year ended **March 31, 2019** ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone Ind AS financial Statement which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statements based on our audit of such standalone financial Statements.
3. We conducted our audit in accordance with the Standard on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement.

An audit involves performing procedures to obtain audited evidence about the amount and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used in the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanation given to us, the Statement:
 - (i) is presented in accordance with the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016; and



(ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and the other accounting principles generally accepted in India of the Net Profit/Loss and Total Comprehensive Income/Loss and other financial information of the Company for the Year ended March 31, 2019.

5. The Statement includes the results for the Quarter ended March 31, 2019 being the balancing figure between audited figures in respect of the full financial year and the audited year to date figures up to the third quarter of the current financial year.

For and on behalf of
A.K. KHATTAR & ASSOCIATES
Chartered Accountants



A handwritten signature in black ink, appearing to read 'A. Khattar', written over the circular stamp.

(A.K. KHATTAR)
(Prop.)
(Membership No.-084960)

Place: Delhi
Date: May 30, 2019



Genomic Valley Biotech Limited

Regd. Off: 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman,
P.O. Tandaheri, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542
Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

Annexure-3


Declaration of Un-Modified Audit Report pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Yogesh Agrawal, Managing Director and Lalit Shah, Chief Financial Officer of Genomic Valley Biotech Limited having its Registered Office at 4 K.M. Stone, Berri Chharra Road, Village- Kherka Musalman, P.O. Tandaheri, Tehsil-Bahadurgarh, Distt- Jhajjar, Haryana-124507, hereby declare that A. K Khattar & Associates, Chartered Accountants (M. No. 084960), Statutory Auditors of the Company, has issued an Auditor Report with Un-Modified opinion on Audited Financial Results of the Company (Standalone) for the quarter and year ended 31st March, 2019.

This declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

For Genomic Valley Biotech Limited

Yogesh Agrawal
Managing Director
DIN No. 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi-110063



Lalit Shah
Chief Financial Officer
PAN No. BCHPS9526B
Address: Flat No. 303, Pacific Tower,
Omaxe City, Rohtak Road,
Bahadurgarh-124507

Dated: 30.05.2019
Place: Delhi